On Thursday, Aurinia Prescribed drugs Inc AUPH reported fourth-quarter earnings of 1 cent per share, in comparison with a lack of 19 cents a yr in the past and the consensus lack of 2 cents.
The biopharma firm reported fourth-quarter gross sales of $59.9 million, up 33% yr over yr, nearly consistent with the consensus of $59.9 million.
- Internet product gross sales of LUPKYNIS, the primary FDA-approved oral remedy for energetic lupus nephritis, have been $57.6 million, up 36%.
- License, collaboration, and royalty income, which incorporates manufacturing providers income and royalties from Aurinia’s collaboration companion, Otsuka, was $2.3 million, down 18%.
Additionally Learn: Taiwan Semiconductor Faces Authorities Scrutiny on Abroad Ventures Amid Intel Stake Rumors
For 2024, internet product gross sales have been $216.2 million, up 36%, inside the administration steering of $210 million-$220 million.
The corporate reported an working lack of $1.67 million in comparison with $29.7 million a yr in the past.
Aurinia reported a internet revenue of $1.43 million, higher than the lack of $26.9 million.
Aurinia CEO Peter Greenleaf expects 2025 to be “an thrilling yr” for the corporate on the subject of rising LUPKYNIS’s adoption. Plans are additionally in place to advance AUR200, which has the potential to deal with “a variety of autoimmune ailments,” he provides.
Steering: Aurinia expects fiscal yr income of $250 million-$260 million versus the consensus of $274.4 million.
Value Motion: Aurinia inventory is down 6.35% at $7.45 on the final Thursday.
Learn Subsequent:
Picture: Shutterstock
Market Information and Information delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
